FDA and FTC warned Medical Mikes over unapproved CBD claims to prevent or treat COVID-19.
What happened
FDA reviewed https://medicalmikes.com/ on December 7, 2022, and FTC reviewed it on January 6, 2023. FDA found the website offered CBD products with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19, including in blog posts. FDA called the products unapproved new drugs, meaning they lack FDA approval for those uses, and misbranded drugs.
What FDA found
The website sold CBD products as drugs for COVID-19 without FDA approval, which violates the unapproved-drug rule.
section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a)The CBD products are misbranded because their labeling makes drug claims without the required approved labeling.
section 502 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 352The company is prohibited from introducing these products into interstate commerce.
sections 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331(a) and (d)The company lacked competent and reliable scientific evidence for claims that its products prevent or treat COVID-19.
FTC Act, 15 U.S.C. § 41 et seq.Making deceptive COVID-19 treatment claims can bring civil penalties under the COVID-19 Consumer Protection Act.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks the company to immediately stop selling any unapproved products claimed for COVID-19 and, within 48 hours, email the FDA task force with the steps taken, how it will prevent recurrence, and related documents. If it cannot complete the actions in 48 hours, it must state why and give a timeframe.
Who should pay attention
- CBD and supplement brands making health claims
- e-commerce sellers with product-related blog content
- companies advertising COVID-19-related treatments
This is a summary. Read the original letter on fda.gov.